Source: Newcomer
Anthropic is betting that Claude’s reasoning capabilities can compress the drug discovery timeline by automating molecular design and protein folding—the labor-intensive work that makes biotech expensive and slow. The $400M acquisition shows AI labs are moving beyond chatbots into verticals with measurable ROI, where a 10% improvement in hit rates or candidate screening affects pharma economics. Anthropic also gains a team already embedded in wet biology rather than retraining its own people, while Coefficient avoids the difficult path of selling enterprise AI tools as a standalone vendor.